Limits...
Orthostatic stability with intravenous levodopa.

Siddiqi SH, Creech ML, Black KJ - PeerJ (2015)

Bottom Line: Levodopa is the precursor for dopamine, and intravenous dopamine would strongly affect vascular tone, but peripheral decarboxylase inhibitors are intended to block such effects.Levodopa caused no statistically or clinically significant changes in blood pressure or pulse.These data add to previous data that support the safety of i.v. levodopa when given with adequate peripheral inhibition of DOPA decarboxylase.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Psychiatry, Washington University School of Medicine , St. Louis, MO , USA.

ABSTRACT
Intravenous levodopa has been used in a multitude of research studies due to its more predictable pharmacokinetics compared to the oral form, which is used frequently as a treatment for Parkinson's disease (PD). Levodopa is the precursor for dopamine, and intravenous dopamine would strongly affect vascular tone, but peripheral decarboxylase inhibitors are intended to block such effects. Pulse and blood pressure, with orthostatic changes, were recorded before and after intravenous levodopa or placebo-after oral carbidopa-in 13 adults with a chronic tic disorder and 16 tic-free adult control subjects. Levodopa caused no statistically or clinically significant changes in blood pressure or pulse. These data add to previous data that support the safety of i.v. levodopa when given with adequate peripheral inhibition of DOPA decarboxylase.

No MeSH data available.


Related in: MedlinePlus

Orthostatic vital signs before and after levodopa infusion.No significant changes were observed between IV levodopa or placebo days in (A) heart rate, (B) systolic blood pressure, or (C) diastolic blood pressure. Values shown are mean ± S.D. for all data. (See Table 2 for means and 95% confidence intervals from the paired analysis.)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556150&req=5

fig-1: Orthostatic vital signs before and after levodopa infusion.No significant changes were observed between IV levodopa or placebo days in (A) heart rate, (B) systolic blood pressure, or (C) diastolic blood pressure. Values shown are mean ± S.D. for all data. (See Table 2 for means and 95% confidence intervals from the paired analysis.)

Mentions: No significant difference was found between vital sign parameters during levodopa versus placebo infusions (Table 2, Fig. 1). Standing increased P and DBP, and the magnitude of this change increased somewhat from earlier to later in the day, but none of these changes differed between levodopa and placebo. The largest absolute orthostatic increases in P, both of which were found on the post-infusion measurements, were 11.7 bpm on the placebo day and 12.3 bpm on the levodopa day. The largest absolute orthostatic increases in DBP, also found on the post-infusion measurements, were 7.4 mmHg in the placebo group and 2.0 mmHg in the levodopa group (p = 0.20). For the differences between levodopa and placebo for all vital sign parameters (supine P/SBP/DBP, standing P/SBP/DBP, orthostatic change in P/SBP/DBP), paired p values ranged between 0.16 (for supine SBP) and 0.92 (for standing SBP). Additionally, no significant difference was found for adverse effect scales (Table 3).


Orthostatic stability with intravenous levodopa.

Siddiqi SH, Creech ML, Black KJ - PeerJ (2015)

Orthostatic vital signs before and after levodopa infusion.No significant changes were observed between IV levodopa or placebo days in (A) heart rate, (B) systolic blood pressure, or (C) diastolic blood pressure. Values shown are mean ± S.D. for all data. (See Table 2 for means and 95% confidence intervals from the paired analysis.)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556150&req=5

fig-1: Orthostatic vital signs before and after levodopa infusion.No significant changes were observed between IV levodopa or placebo days in (A) heart rate, (B) systolic blood pressure, or (C) diastolic blood pressure. Values shown are mean ± S.D. for all data. (See Table 2 for means and 95% confidence intervals from the paired analysis.)
Mentions: No significant difference was found between vital sign parameters during levodopa versus placebo infusions (Table 2, Fig. 1). Standing increased P and DBP, and the magnitude of this change increased somewhat from earlier to later in the day, but none of these changes differed between levodopa and placebo. The largest absolute orthostatic increases in P, both of which were found on the post-infusion measurements, were 11.7 bpm on the placebo day and 12.3 bpm on the levodopa day. The largest absolute orthostatic increases in DBP, also found on the post-infusion measurements, were 7.4 mmHg in the placebo group and 2.0 mmHg in the levodopa group (p = 0.20). For the differences between levodopa and placebo for all vital sign parameters (supine P/SBP/DBP, standing P/SBP/DBP, orthostatic change in P/SBP/DBP), paired p values ranged between 0.16 (for supine SBP) and 0.92 (for standing SBP). Additionally, no significant difference was found for adverse effect scales (Table 3).

Bottom Line: Levodopa is the precursor for dopamine, and intravenous dopamine would strongly affect vascular tone, but peripheral decarboxylase inhibitors are intended to block such effects.Levodopa caused no statistically or clinically significant changes in blood pressure or pulse.These data add to previous data that support the safety of i.v. levodopa when given with adequate peripheral inhibition of DOPA decarboxylase.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Psychiatry, Washington University School of Medicine , St. Louis, MO , USA.

ABSTRACT
Intravenous levodopa has been used in a multitude of research studies due to its more predictable pharmacokinetics compared to the oral form, which is used frequently as a treatment for Parkinson's disease (PD). Levodopa is the precursor for dopamine, and intravenous dopamine would strongly affect vascular tone, but peripheral decarboxylase inhibitors are intended to block such effects. Pulse and blood pressure, with orthostatic changes, were recorded before and after intravenous levodopa or placebo-after oral carbidopa-in 13 adults with a chronic tic disorder and 16 tic-free adult control subjects. Levodopa caused no statistically or clinically significant changes in blood pressure or pulse. These data add to previous data that support the safety of i.v. levodopa when given with adequate peripheral inhibition of DOPA decarboxylase.

No MeSH data available.


Related in: MedlinePlus